MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion [Seeking Alpha]
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration [Globe and Mail, The (Toronto, Canada)]
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets [Globe and Mail, The (Toronto, Canada)]